Literature DB >> 11037342

In situ reverse-transcriptase polymerase chain reaction demonstration of the EWS/FLI-1 fusion transcript in Ewing's sarcomas and peripheral primitive neuroectodermal tumors.

M Krams1, J Peters, F Boeckel, A Raether, P F Ambros, R Parwaresch, D Harms.   

Abstract

It is now widely accepted that the EWS/FLI-1 fusion transcript is associated with tumors of the Ewing family. To test whether it is possible to detect the fusion transcript by means of combining polymerase chain reaction (PCR) methodology and immunohistochemistry, we investigated tumors of the Ewing family using in situ reverse transcriptase (RT)-PCR. We were able to demonstrate the t(11;22) fusion transcript in five of six cases of Ewing's sarcoma and four of four peripheral primitive neuroectodermal tumors. These results were confirmed using fluorescence in situ hybridization in seven tumor samples. In situ RT-PCR-labeled fusion transcripts were found in virtually all tumor cells within a given sample, indicating that each cell possessed the t(11;22) transcript. We conclude from these results that in situ RT-PCR can be used for the rapid detection of EWS/FLI-1 fusion transcripts in biopsy material. The findings also suggest that all cells of the tumors of the Ewing family carry the EWS/FLI-1 fusion transcript.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11037342     DOI: 10.1007/s004280000252

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  1 in total

1.  Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group.

Authors:  John A van Doorninck; Lingyun Ji; Betty Schaub; Hiroyuki Shimada; Michele R Wing; Mark D Krailo; Stephen L Lessnick; Neyssa Marina; Timothy J Triche; Richard Sposto; Richard B Womer; Elizabeth R Lawlor
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.